Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Benitec Biopharma, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed HNSCC
Failed (or are ineligible/decline to receive) all available standard therapies
Stable, treated brain metastases
One target lesion defined as measurable (via RECIST v1.1), with a maximum longest diameter of 4 cm, and suitable for injection
Eastern Cooperative Oncology Group (ECOG) 0-2
Agree to biopsies of a selected primary lesion and where possible of a second untreated lesion at baseline and end of treatment
Ceased anti-cancer therapy for at least 3 weeks or 5 half-lives for chemotherapy based treatment regimen, or 4 weeks from any therapy with therapeutic biologicals or any type of investigational therapy
You may not be if
Nasopharyngeal Carcinoma
Concomitant anti-cancer therapy
Unresolved toxicities from prior treatments
Patients in whom the indicator lesion is at risk of hemorrhage or clinically significant swelling/inflammation